| __timestamp | Agios Pharmaceuticals, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 2254600000 |
| Thursday, January 1, 2015 | 141827000 | 2645000000 |
| Friday, January 1, 2016 | 220163000 | 2611000000 |
| Sunday, January 1, 2017 | 292681000 | 2548000000 |
| Monday, January 1, 2018 | 1397000 | 2351000000 |
| Tuesday, January 1, 2019 | 1317000 | 2350000000 |
| Wednesday, January 1, 2020 | 2805000 | 2249000000 |
| Friday, January 1, 2021 | 18777000 | 2394000000 |
| Saturday, January 1, 2022 | 1704000 | 2364000000 |
| Sunday, January 1, 2023 | 9504000 | 2559000000 |
| Monday, January 1, 2024 | 4165000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, Bausch Health Companies Inc. and Agios Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue. Bausch Health consistently maintained a high cost of revenue, averaging around $2.4 billion annually, with a slight increase of 11% from 2014 to 2023. In contrast, Agios Pharmaceuticals experienced a dramatic 90% decrease in cost of revenue from 2017 to 2018, reflecting strategic shifts or operational changes. By 2023, Agios's cost of revenue was a mere fraction of Bausch's, highlighting differing business models and market strategies. This analysis underscores the importance of cost management in sustaining competitive advantage in the pharmaceutical sector.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Amgen Inc. vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Agios Pharmaceuticals, Inc.
Bio-Techne Corporation vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Xenon Pharmaceuticals Inc. and Bausch Health Companies Inc.
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored